Literature DB >> 8270255

Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours.

P A Crossey1, K Foster, F M Richards, M E Phipps, F Latif, K Tory, M H Jones, E Bentley, R Kumar, M I Lerman.   

Abstract

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome characterised by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma (RCC), phaeochromocytoma and pancreatic tumours. The VHL disease gene maps to chromosome 3p25-p26. To investigate the mechanism of tumourigenesis in VHL disease, we analysed 24 paired blood/tumour DNA samples from 20 VHL patients for allele loss on chromosome 3p and in the region of tumour suppressor genes on chromosomes 5, 11, 13, 17 and 22. Nine out of 24 tumours showed loss of heterozygosity (LOH) at at least one locus on chromosome 3p and in each case the LOH included the region to which the VHL gene has been mapped. Chromosome 3p allele loss was found in four tumour types (RCC, haemangioblastoma, phaeochromocytoma and pancreatic tumour) suggesting a common mechanism of tumourigenesis in all types of tumour in VHL disease. The smallest region of overlap was between D3S1038 and D3S18, a region that corresponds to the target region for the VHL gene from genetic linkage studies. The parental origin of the chromosome 3p25-p26 allele loss could be determined in seven tumours from seven familial cases; in each tumour, the allele lost had been inherited from the unaffected parent. Our results suggest that the VHL disease gene functions as a recessive tumour suppressor gene and that inactivation of both alleles of the VHL gene is the critical event in the pathogenesis of VHL neoplasms. Four VHL tumours showed LOH on other chromosomes (5q21, 13q, 17q) indicating that homozygous VHL gene mutations may be required but may not be sufficient for tumourigenesis in VHL disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8270255     DOI: 10.1007/bf00218913

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  29 in total

1.  Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma.

Authors:  R Morita; S Saito; J Ishikawa; O Ogawa; O Yoshida; K Yamakawa; Y Nakamura
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

2.  Specific genetic change in tumors associated with von Hippel-Lindau disease.

Authors:  K Tory; H Brauch; M Linehan; D Barba; E Oldfield; M Filling-Katz; B Seizinger; Y Nakamura; R White; F F Marshall
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

3.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

4.  Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus.

Authors:  P A Crossey; E R Maher; M H Jones; F M Richards; F Latif; M E Phipps; M Lush; K Foster; K Tory; J S Green
Journal:  Hum Mol Genet       Date:  1993-03       Impact factor: 6.150

5.  Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.

Authors:  E R Maher; J R Yates; M A Ferguson-Smith
Journal:  J Med Genet       Date:  1990-05       Impact factor: 6.318

6.  Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism.

Authors:  M H Jones; Y Nakamura
Journal:  Genes Chromosomes Cancer       Date:  1992-07       Impact factor: 5.006

7.  Nonhomologous chromatid exchange in hereditary and sporadic renal cell carcinomas.

Authors:  G Kovacs; H F Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

8.  Mapping of von Hippel-Lindau disease to chromosome 3p confirmed by genetic linkage analysis.

Authors:  E R Maher; E Bentley; J R Yates; D Barton; A Jennings; I W Fellows; M A Ponder; B A Ponder; C Benjamin; R Harris
Journal:  J Neurol Sci       Date:  1990-12       Impact factor: 3.181

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p.

Authors:  M H Jones; K Yamakawa; Y Nakamura
Journal:  Hum Mol Genet       Date:  1992-05       Impact factor: 6.150

View more
  41 in total

Review 1.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

2.  Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.

Authors:  A O Vortmeyer; I A Lubensky; F Fogt; W M Linehan; U Khettry; Z Zhuang
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  VHL-deficient vasculogenesis in hemangioblastoma.

Authors:  Sven Gläsker; Jonathan Smith; Mark Raffeld; Jie Li; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Exp Mol Pathol       Date:  2014-01-04       Impact factor: 3.362

4.  Aberrant methylation in cancer.

Authors:  R Versteeg
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

5.  Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.

Authors:  S Gläsker; B U Bender; T W Apel; V van Velthoven; L M Mulligan; J Zentner; H P Neumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

6.  A review of vascular anomalies: genetics and common syndromes.

Authors:  Elizabeth Killion; Kriti Mohan; Edward I Lee
Journal:  Semin Plast Surg       Date:  2014-05       Impact factor: 2.314

7.  Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Authors:  H J Decker; C Neuhaus; A Jauch; M Speicher; T Ried; M Bujard; H Brauch; S Störkel; M Stöckle; B Seliger; C Huber
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas.

Authors:  Cezary Cybulski; Joanna Matyjasik; Marianna Soroka; Janusz Szymaś; Bohdan Górski; Tadeusz Debniak; Anna Jakubowska; Andrzej Bernaczyk; Lech Zimnoch; Grazyna Bierzyńska-Macyszyn; Tomasz Trojanowski; Teresa Wierzba-Bobrowicz; Edmund Prudlak; Alicja Markowska-Wojciechowska; Przemysław Nowacki; Andrzej Roszkiewicz; Radzisław Kordek; Tadeusz Szylberg; Ewa Matyja; Krzysztof Zieliński; Bogdan Woźniewicz; Anna Taraszewska; Wojciech Kozłowski; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2004-03-15       Impact factor: 2.857

9.  Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.

Authors:  C Eng; P A Crossey; L M Mulligan; C S Healey; C Houghton; A Prowse; S L Chew; P L Dahia; J L O'Riordan; S P Toledo
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.